UBS AM’s Lifecore Biomedical LFCR Stock Holding History
Bought
Maintained
Sold
Other funds holding LFCR
DA
UBS AM's LFCR Position: Q3 2026 in Review
UBS AM opened a new position in Lifecore Biomedical (LFCR) in Q3 2026: 295 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #4050 among its holdings. This is a return to the name: UBS AM previously reported a position in LFCR as recently as Q3 2013.
UBS AM first reported a position in LFCR in Q2 2013 and has held it in 3 quarters since. The position peaked at $243K in Q2 2013. 90 funds tracked by Wall St. Rank hold LFCR as of Q3 2026.
- UBS AM held 295 shares of Lifecore Biomedical worth $1.94K as of Q3 2026.
- Lifecore Biomedical was a new UBS AM position in Q3 2026.
- Lifecore Biomedical made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4050 holding.
- UBS AM first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 3 quarters since.
- UBS AM's Lifecore Biomedical position peaked at $243K in Q2 2013.
- 90 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.